| 靶点: |
IC50: 1.5 µM (Rho-pathway selective serum response element-luciferase reporter) |
| 体内研究: |
CCG-1423 (0.15 mg/kg;腹腔注射,每日一次,持续两周) 影响高脂饮食喂养小鼠的葡萄糖耐量和胰岛素水平。 |
| 参考文献: |
1. Evelyn CR, et al. Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. Bioorg Med Chem Lett. 2010 Jan 15;20(2):665-72. 2. Jin W, et al. Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest. 2011 Mar;121(3):918-29. 3. Evelyn CR, et al. CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol Cancer Ther. 2007 Aug;6(8):2249-60. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.199 ml |
10.995 ml |
21.99 ml |
| 5 mM |
0.44 ml |
2.199 ml |
4.398 ml |
| 10 mM |
0.22 ml |
1.1 ml |
2.199 ml |
| 50 mM |
0.044 ml |
0.22 ml |
0.44 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |